Holen Sie sich die Stockscreener-App
78.01
0.79%
0.61
Handel nachbörslich:
78.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$77.40
Offen:
$79.11
24-Stunden-Volumen:
1.46M
Relative Volume:
0.89
Marktkapitalisierung:
$38.02B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
39.50
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
+4.63%
1M Leistung:
-3.27%
6M Leistung:
+8.27%
1J Leistung:
-10.33%
1-Tages-Spanne:
$77.54
$79.11
1-Wochen-Bereich:
$73.92
$79.11
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
78.01 | 37.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
450.62 | 161.58B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.22 | 44.22B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.60 | 37.08B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
228.87 | 33.21B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon launches Clareon TruPlus monofocal and toric IOL - Eyes On Eyecare
Alcon Inc stock: What you need to know before investing now - AD HOC NEWS
Assessing Alcon (SWX:ALC) Valuation After Clareon TruPlus Lens Launch At ASCRS Meeting - Yahoo Finance
Is It Time To Reconsider Alcon (SWX:ALC) After Its 15.5% One Year Share Price Decline - Yahoo Finance
Sight Sciences wins $34M patent ruling against Alcon - MSN
Mexican Gold Mining Corp. and Alcon Silver Corp. Announce Arrangement Agreement to Create a Diversified Precious Metals Exploration Company - TMX Newsfile
Bridges Investment Fund's Alcon Inc(ALC) Holding History - GuruFocus
Alcon Inc (ALC) Trading 3.96% Higher on Apr 8 - GuruFocus
AB SUSTAINABLE INTERNATIONAL THEMATIC FUND INC's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
Alcon Shares Rise After Introducing Clareon TruPlus at ASCRS - Bitget
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS - Yahoo Finance
Alcon Inc. stock: Why eye health leader stands out for investors now - AD HOC NEWS
U.S. Federal Trade Commission – Proposed Merger Between Alcon, Inc. And Lensar, Inc. Abandoned Following Competition Concerns - marketscreener.com
Former Alcon executive named as chief operating officer at biotech company Nanoscope - Fort Worth Report
Alcon Inc stock: What you should know about its eye care leadership now - AD HOC NEWS
Blue Jays eye-drop deal spotlights dry eye for 8.5 million Canadians - Stock Titan
Alcon Inc stock: What investors should know about its eye care leadership now - AD HOC NEWS
Alcon Announces U.S. Launch of Clareon TruPlus IOLs - VisionMonday.com
Alcon (ALC) Launches Clareon TruPlus Intraocular Lens in the U.S. - GuruFocus
Alcon Rolls Out Clareon TruPlus Intraocular Lens in U.S. - Medical Product Outsourcing
Alcon Inc. (ALC) Stock Price, News, Quote & History - Yahoo Finance
Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026 - Yahoo Finance
Alcon Expands Manufacturing in West Virginia With $81 Million Investment - VisionMonday.com
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target Reset - Yahoo Finance
Alcon Sets April 30, 2026 AGM, Proposes New Director and CHF 0.28 Dividend - The Globe and Mail
Alcon Inc stock: Steady eye care leader amid market pressures? - AD HOC NEWS
Systane eye drops: Are Alcon’s German bestsellers worth it in the US? - AD HOC NEWS
Nanoscope Therapeutics Names Former Alcon Exec as Its New COO - National Today
Alcon Inc. (ALC) stock price, news, quote and history - Yahoo Finance Singapore
Alcon (NYSE: ALC) plans CHF 0.28 dividend and board votes at 2026 AGM - Stock Titan
Alcon Publishes Agenda for 2026 Annual General Meeting - Business Wire
Nanoscope brings in Alcon veteran as COO ahead of launch phase - The Pharma Letter
Alcon Inc. announces Annual dividend, payable on May 07, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and HCA Healthcare (HCA) - theglobeandmail.com
Systane Eye Drops: Alcon's Leading Dry Eye Relief Product Driving Steady Growth in North American Op - AD HOC NEWS
List of 19 Acquisitions by Alcon (Apr 2026) - Tracxn
Lensar outlines 46%–49% gross margin forecast for 2026 as it restarts growth after Alcon deal termination - MSN
Alcon Inc Stock Faces Patent Setback and Merger Termination: Key Implications for NYSE:ALC Investors - AD HOC NEWS
Sight Sciences wins $34M in Alcon patent case, ongoing royalty By Investing.com - Investing.com South Africa
ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill
Volume Report: Is Alcon Inc benefiting from innovation trendsDay Trade & Verified High Yield Trade Plans - baoquankhu1.vn
Street Watch: Should I hold or sell Alcon Inc now2026 PreEarnings & Weekly Top Stock Performers List - baoquankhu1.vn
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - au.investing.com
Alcon (ALC) Faces $34 Million Verdict in Patent Case - GuruFocus
Alcon Fails to Undo $34 Million Patent Loss, Must Pay Royalties - Bloomberg Law News
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):